A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma

  • Huili Ma
  • Yongfei Xue
  • Changsheng Li
  • Jingwei Zhang
  • Zhonghai Ren
Article

Abstract

Objective

Molecular targeted drugs have been widely used in clinical application which has successfully prolonged some patients’ life. Meanwhile, molecular targeted drug therapy for esophageal cancer are attracting more and more attention from doctors and experts. However, little study has been done towards the effect of this approach for treating esophageal squamous cell carcinoma. This paper, therefore, intends to explore the possibilities of applying EGFR-TKI inhibitors or anti-EGFR monoclonal antibody in esophageal squamous cell carcinoma by studying the mutations of EGFR, K-ras and B-raf in the esophageal squamous cell carcinoma tissues.

Methods

Thirty-five cases of resected specimens of diagnosed esophageal squamous cell carcinoma with complete clinical and pathological data from January to April 2009 were collected. Pyrophosphate was used for observing the mutations of EGFR, K-ras and B-raf in the esophageal squamous cell carcinoma tissues.

Results

Examinations were undertaken respectively to the codon segment 746–754 of exon 19 in EGFR genes, codon 12 and 13 in K-ras genes as well as condon 600 in B-raf genes. No mutation was found in EGFR and B-raf genes with mutation rate 0% (0/35), all of codon 12 in K-ras genes were wild-type without any mutation, while 2 specimens of codon 13 had mutations with mutation rate of 5.71% (2/35).

Conclusion

In treating esophageal squamous cell carcinoma patients, all K-ras genes are expressed as wild type due to low mutation rate; cetuximab is effective due to low mutation rate of B-raf while EGFR-TKI inhibitor will not be effective enough because of low mutation rate of EGFR genes.

Key words

carcinoma of esophagus mutation pyro-sequencing molecular targeted drugs gene 

References

  1. 1.
    Wu YL, Sun Y. Cancer management can be personalized? -Cancer genomic research in China. Chinese-German J Clin Oncol, 2006, 5: 156–158.CrossRefGoogle Scholar
  2. 2.
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with efinical response to gefitinib therapy. Science, 2004, 304: 1497–1500.PubMedCrossRefGoogle Scholar
  3. 3.
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129–2139.PubMedCrossRefGoogle Scholar
  4. 4.
    Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinibin second-line treatment of advanced esophageal cancer patients. J Clin Oncol, 2006, 24: 1612–1619.PubMedCrossRefGoogle Scholar
  5. 5.
    Guo M, Liu S, Herman JG, et al. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther, 2006, 5:152–155.PubMedCrossRefGoogle Scholar
  6. 6.
    Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med, 2006, 354: 2193–2194.PubMedCrossRefGoogle Scholar
  7. 7.
    Pühringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett’s) adenocarcinomas. Dis Esophagus, 2007, 20: 9–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Sudo T, Mimori K, Nagahara H, et al. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol, 2007, 33: 44–48.PubMedGoogle Scholar
  9. 9.
    Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer, 2006, 118: 1173–1180.PubMedCrossRefGoogle Scholar
  10. 10.
    De Vita F, Orditura M, Martinelli E, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced esophageal cancer. Br J Cancer, 2011, 104: 427–432.PubMedCrossRefGoogle Scholar
  11. 11.
    Gonçalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer, 2008, 8: 169.PubMedCrossRefGoogle Scholar
  12. 12.
    Lyronis ID, Baritaki S, Bizakis I. K-ras mutation, et al. HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res, 2008, 14: 267–273.PubMedCrossRefGoogle Scholar
  13. 13.
    Arber N, Shapira I, Ratan J. et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology, 2000, 118: 1045–1050.PubMedCrossRefGoogle Scholar
  14. 14.
    Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type B-raf is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26: 5668–5670.CrossRefGoogle Scholar
  15. 15.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417: 949–954.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Huili Ma
    • 1
  • Yongfei Xue
    • 1
  • Changsheng Li
    • 1
  • Jingwei Zhang
    • 1
  • Zhonghai Ren
    • 1
  1. 1.Departments of OncologyNanyang Center HospitalNanyangChina

Personalised recommendations